← Takaisin Mallit-sivulle

Tekoälymallien arviot osakkeelle
Orion Oyj B markkinahintaan verrattuna

2026-06-17🇫🇮 OMXHhealthcare
67.20 EUR
52 viikon vaihteluväli
56.50 €
75.30 €

Tilanne 2026-06-17: 5 AI-mallia arvioi ORNBV:n mediaaniksi 92.66 € (+37.9% suhteessa spotiin 67.20 €, mallien yksimielisyys 0.81). Analyytikkokonsensus 74.17 € (6 analyytikkoa). Kokeellinen vertailu — ei sijoitusneuvontaa.

AI-konsensus

Mallin arvio
92.66 €
Sis. 30 % analyytikkoankkurointi
Ero
+37.9%
Yksimielisyys
0.815/5 mallia
Raaka 0.76
Hajonta
σ 0.08
Analyytikkokonsensus
74.17 €(6 analyytikkoa)
AI-yhteenveto
5 viidestä AI-mallia on positiivisia ORNBV. Avaintekijä: Continued strong revenue growth, supported by the company's oncology pipeline... AI-konsensusarvio 92.66 37.9% yli nykyhinnan. Mallien yksimielisyys on korkea (0.81). Analyytikkokonsensus: 74.17 (AI +24.9%).
gptclaudegeminideepseekgrokORNBVOrion Oyj B67.2spot74.2analysts62.372.482.592.6103113
Pessimistinen (min)
95.06 €
41.5%
Perus (mediaani)
92.66 €
+37.9%
Optimistinen (max)
122.40 €
82.1%

Arvion kehitys AI-mallien arviot ja osakkeen hinta ajan yli

Loading...

Mikä muuttui tänään

Konsensusarvio:93.06→92.66(-0.4%)
no-changesteady-statepipeline-optionality-noted

Mallien erittely

GEMINI →
Est.
107.93
Ero
+60.6%
Conf
0.80
DCF 122.40 → Kal. 107.93
Avaintekijät
  • Continued strong revenue growth, supported by the company's oncology pipeline…
  • Sustained high EBIT margins, reflecting the value of proprietary pharmaceutic…
  • Diversified product portfolio spanning human and veterinary pharmaceuticals a…
Suurin riski
  • Potential impact of patent expirations on key revenue-generating drugs.
  • Uncertainty in R&D success rates and the timeline for new product approvals.
  • Intense competition within the global pharmaceutical market.
Muutos
No significant changes in key valuation assumptions compared to yesterday's model.
Ei muutosta
no change
CLAUDE →
Est.
104.57
Ero
+55.6%
Conf
0.73
DCF 117.60 → Kal. 104.57
Avaintekijät
  • Nubeqa (darolutamide) royalty stream from Bayer partnership remains the prima…
  • Historical revenue CAGR of 12.1% (2022–2025: €1.34B→€1.89B) and analyst conse…
  • Trailing EBIT margin of 32.2% is well above the healthcare/pharma sector typi…
Suurin riski
  • Nubeqa royalty concentration: a significant share of current profitability depends on B…
  • Post-peak royalty margin compression: as Nubeqa royalties plateau or decline, the blend…
  • Pipeline execution risk: Hippo pathway and other oncology candidates are early-stage; c…
Muutos
All four core valuation assumptions are unchanged from the prior day model (2026-06-16). No new material financial da…
Ei muutosta
no-changesteady-statepipeline-optionality-noted
GPT →
Est.
92.66
Ero
+37.9%
Conf
0.75
DCF 100.58 → Kal. 92.66
Avaintekijät
  • Strong growth in oncology and psychiatric medications
  • Expansion into new markets
  • R&D pipeline supporting future growth
Suurin riski
  • Potential patent expirations impacting revenues
  • Regulatory challenges
  • Market competition and pricing pressures
Muutos
No significant changes in assumptions have been noted since yesterday. The outlook remains stable with confidence in …
Ei edellistä dataa
assumptionsgrowth
GROK →
Est.
90.84
Ero
+35.2%
Conf
0.65
DCF 97.98 → Kal. 90.84
Avaintekijät
  • Nubeqa and oncology pipeline expansion
  • Easyhaler respiratory portfolio scale
  • Historical revenue CAGR 12.1% moderating to sustainable levels
Suurin riski
  • Patent cliff exposure on key molecules
  • R&D spend pressure on near-term margins
  • Regulatory approval delays for pipeline assets
Muutos
No material change in assumptions; updated as-of date only.
Ei edellistä dataa
date roll
DEEPSEEK →
Est.
88.80
Ero
+32.1%
Conf
0.70
DCF 95.06 → Kal. 88.80
Avaintekijät
  • Strong historical revenue CAGR of 12.1% driven by Nubeqa and Easyhaler portfolio
  • Oncology pipeline (Hippo pathway data) adds new growth dimension
  • Record 2025 results and dividend hike signal confidence in capital allocation
Suurin riski
  • Patent expirations on key products (e.g., Entacapone, Stalevo) could pressure revenue
  • Concentration risk from Nubeqa and Parkinson's franchise
  • Regulatory and pricing pressure in European pharma markets
Muutos
No material change in assumptions from yesterday's model; all four inputs remain the same.
Ei muutosta
no change

Arvostusoletukset

CLAUDEDEEPSEEKGEMINIGPTGROK
Liikevaihdon CAGR 5V9.0%8.0%12.0%10.0%8.0%
EBIT-marginaalitavoite31.0%32.0%32.0%35.0%33.0%
WACC7.5%8.5%8.5%9.5%8.5%
Terminaalikasvu2.0%2.0%2.0%2.0%2.0%

Mitä markkinahinta edellyttäisi?

OletusAI-konsensusMarkkinahinta implikoi
Liikevaihdon CAGR (5v)9.0%2.6%-6.4pp
EBIT-marginaalitavoite32.0%21.1%-10.9pp
WACC8.5%11.4%+2.9pp
Perustuu spot-hintaan 67.20 € ja raakaan DCF-malliin (ilman kattoja ja kalibrointia).

Tunnusluvut

EBIT-marginaali32.2%
EBITDA-marginaali36.9%
ROE41.2%
Nettovelka / EBITDA0.2x
P/E17.9x
EV / EBITDA13.3x
P/B8.4x
Analyytikkojen vaihteluväli55.00 – 81.00
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing
Lähde: Yahoo Finance

Viimeisimmät uutiset

Orion Oyj Hippo Pathway Data Adds New Dimension To Oncology Story2026-06-03
Orion Oyj (ORINF) Q1 2026 Earnings Call Highlights: Robust Growth and Strategic Outlook2026-04-24
Is Orion Oyj (HLSE:ORNBV) Still Attractive After Strong Multi‑Year Share Price Gains?2026-03-11
Assessing Orion Oyj’s Valuation After Recent Share Price Strength And Long Term Returns2026-03-11

Lisää healthcare-sektorilta

JNJ · Johnson & Johnson
Tilaa sähköpostiuutisetIlmainen · Ei roskapostia · Peruuta milloin vain · Tietosuoja
AI Investor Barometer · 2026-06-17
Kaikki sisältö on tekoälymallien tuottamaa ja voi sisältää virheitä. Tämä on kokeellinen työkalu — ei sijoitusneuvontaa, -tutkimusta eikä -suositusta. Tietoa · Metodologia · Käyttöehdot · Tietosuoja